Correlates of SGLT-2-inhibitiors use among patients with atherosclerotic cardiovascular disease and type 2 diabetes mellitus: Insights from the department of veterans affairs - 28/04/22
Doi : 10.1016/j.ahj.2021.12.006
Mahmoud Al Rifai, MD,MPH a, Dhruv Mahtta, DO,MBA a, b, David J. Ramsey, PhD b, Michelle T. Lee, MD a, b, Chayakrit Krittanawong, MD a, Sankar D. Navaneethan, MD,MS,MPH c, L. Parker Gregg, MD,MS d, Laura A. Petersen, MD,MPH a, e, Salim S. Virani, MD,PhD a, b, f, g, ⁎ 
a Department of Medicine, Section of Cardiology, Baylor College of Medicine, Houston, TX
b Health Policy, Quality & Informatics Program, Michael E. DeBakey VA Medical Center Health Services Research & Development Center for Innovations in Quality, Effectiveness, and Safety, Houston, TX
c Section of Nephrology and Institute of Clinical and Translational Research, Baylor College of Medicine, and Michael E. DeBakey VA Medical Center, Houston, TX
d Department of Medicine,Section of Nephrology, Baylor College of Medicine, Houston, TX
e Section of Health Services Research, Baylor College of Medicine, Houston, TX
f Department of Medicine, Section of Cardiovascular Research, Baylor College of Medicine, Houston, TX
g Section of Cardiology, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX
⁎Reprint requests: Salim S. Virani, MD, PhD, Health Services Research and Development (152), Michael E. DeBakey Veterans Affairs Medical Center, 2002 Holcombe Blvd, Houston, TX 77030Health Services Research and Development (152)Michael E. DeBakey Veterans Affairs Medical Center2002 Holcombe BlvdHoustonTX77030
Résumé |
This study using data from the Veterans Affairs (VA) administrative and clinical dataset examined determinants of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) use among patients with concomitant atherosclerotic cardiovascular disease (ASCVD) and diabetes mellitus. The aim of the present analysis was to identify barriers and facilitators associated with SGLT-2i in a real-world contemporary patient population in order to improve utilization of these guideline-directed agents.
Le texte complet de cet article est disponible en PDF.Mots-clés : SGLT-2i, ASCVD
Plan
© 2021
Publié par Elsevier Masson SAS.
Vol 248
P. 160-162 - juin 2022 Retour au numéro
Article précédent
- Trends in PCSK9 inhibitor utilization in the United States, Europe, and other countries: An analysis of international sales data
- Joseph Edgar Blais, Yue Wei, Martin Knapp, Ian C.K. Wong, Li Wei, Esther W. Chan
- The safety of flecainide for atrial fibrillation in patients with stable coronary artery disease – Fact or fallacy
- James A. Reiffel
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?